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ABSTRACT  
Plant based formulations have been used since ancient times and playing a role as a remedial against various human and animal  diseases. The 
interest in traditional medicines has increased in various parts of world. A well known ancient fruit named as Punica granatum (family- 
Punicaceae) which is commonly known as Pomegranate, Anar or Dalim in North India whose therapeutic qualities have rebounded and echoed 
throughout the millennia and regarded as an agent of resurrection for Babylonians; symbol of invincibility on the battle fields for the Persians, 
while for the ancient Chinese, symbolized for longevity and immortality. Punicalagin is chemically named as 2,3-(S)-hexahydroxydiphenoyl-4,6-
(S,S)-gallagyl-D-glucose and belongs to a category of hydrolysable tannin. In this vein, present investigation was an endeavor to formulate the 
vesicular formulation of Punicalagin. For this, the Punicalagin was extracted, isolated and purified from peels of Punica granatum. Thus, to 
protect its hydrolysis, it is formulated into a nanocarrier system known as niosomes which is based on the preparation of niosomes by using a non-
ionic surfactant in varying amounts and keeping the amount of cholesterol constant. The formulations were evaluated on the basis of evaluation 
parameters and thus optimized for the best formulation. 
Keywords: Punica granatum, Punicalagin, Novel Drug Delivery System, Niosomes, Vesicular system. 
Abbreviations used- EA- Ellagic acid, NSV- Non-ionic surfactant vesicles, TEM- transmission electron microscopy, rpm- revolutions per 
minute, v/v- volume by volume 
INTRODUCTION  
Plants itself offer an immense and prodigious, but not 
impossible challenge for anyone trying to work out in 
detail the products of their chemical machinery. Tannins 
are one of the most widely occurring groups of substances 
in different families of higher plants. They are high 
molecular weight plant polyphenols1 and the secondary 
metabolites which are present in solution form in cell sap 
and also in distinct vacuoles. Chemically, tannins contain 
the mixture of complex organic substances in which 
polyphenols are present, generally with o-dihydroxy or o-
trihydroxy groups on phenyl ring and they are devoid of 
nitrogen2. 
The pomegranate (L. Punica granatum) belongs to family 
Punicaceae is commonly known as Anar or Dalim in 
North India3. It is an ancient fruit which has been widely 
consumed in various cultures for thousands and thousands 
of years. The Babylonians regarded pomegranate seeds as 
an agent of resurrection; the Persians believed the seeds 
conferred invincibility on the battle fields, while for the 
ancient Chinese, the seeds symbolized longevity and 
immortality4.Pomegranate husk is a traditional Chinese 
medicine used as antibacterial, anti-inflammatory and 
hemostasis agent which is rich in phenolic compounds. 
Among these polyphenols, the most abundant compound 
is Punicalagin. Punicalagin levels in husk depend upon the 
area for fruit growth, processing conditions as well as 
storage conditions5. Punicalagin is a potent antioxidant 
whose bioactivity can be explained by its ability to 
hydrolyze into Ellagic acid (EA) in vivo and across the 
mitochondrial membrane in vitro.  
For the better performance of pharmaceutical formulations 
with respect to controlled release, bioavailability, storage 
stability and lesser side effects constitute the main 
motivation for research of novel drug delivery systems6. 
Novel drug delivery systems are used to improve the drug 
potency, control drug release to give sustained therapeutic 
effect, provide safety and reduces toxic effects. It may 
target/delivery of drugs specifically to tissue, organ or 
location in the body. There are various novel drug 
delivery strategies like liposomes, niosomes, aquasomes, 
microsponges, microemulsions, and solid lipid 
nanoparticles to enhance the topical delivery of agents. 
Among different carriers, liposomes and niosomes are 
well documented for dermal drug delivery7.Vesicles 
formed on hydration of mixture of cholesterol and single 
alkyl-chain non-ionic surfactants were first introduced by 
Handjani-Vila. Initially reported as a feature of cosmetic 
industry, they are now extensively used as drug delivery 
systems6. 
Niosomes may be defined as a unilamellar or 
multilamellar vesicles in which the aqueous solution is 
enclosed in highly ordered bilayers made up of non-ionic 
surfactants with or without cholesterol and 
dicetylphosphate and exhibit behaviour similar to 
liposomes in-vivo7. They are capable of entrapping both 
hydrophilic and hydrophobic drugs as shown in figure 1. 
Surfactants play an important role in the development of 
such formulations. A number of non-ionic surfactants 
have been used to prepare vesicles viz. polyglycerol alkyl 
ethers, glucosyl dialkyl ethers, crown ethers, ester linked 
surfactants, polyoxyethylene alkyl ether, brij, and series of 
spans and tweens. They are made up of biocompatible, 
non-toxic, non-immunogenic, and non-carcinogenic 
agents. NSV’s are highly resistant to hydrolytic 
degradation. NSVs result from the self assembly of 
hydrated surfactant monomers. The surfactant molecules 
self-assemble in aqueous media in such a fashion that the 
hydrophobic tails face each other to minimize the high 
energy interactions between the solvent and tails6. 
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Figure 1: Microscopic structure of a niosome 
Advantages of niosomes are: accommodate hydrophilic, 
lipophilic as well as amphiphilic drug moieties; niosomes 
exhibit flexibility in their structural characteristics 
(composition, fluidity and size) and can be designed 
according to the desired situation; improve the therapeutic 
performance of the drug, protect from the biological 
environment, restricts its effect to target cells, thereby 
reducing the clearance of drug; act as depot to release the 
drug slowly and offer a controlled/sustained release; 
increase oral bioavailability of drug; increase the stability 
of entrapped drug; enhance the skin penetration of 
drugs8,9. They can be made to reach the site of action by 
oral, parenteral as well as topical routes; surfactants used 
are biodegradable, biocompatible and non-immunogenic; 
handling and storage of surfactants do not require any 
special conditions; the vesicle suspension being water 
based offers greater patient compliance over oily dosage 
forms10, 11. 
The objective of the present study is to develop and 
validate a simple, precise, accurate, and economical 
analytical method for the estimation of Punicalagin 
extracted from peels of Punica granatum. To perform the 
compatibility study of drug, Punicalagin with the 
excipients used in formulating niosomes. To develop a 
vesicular system like niosomes which act as carriers and 
hence will help in penetration of drug through skin and 
provide a prolong release.  
MATERIALS  
Punicalagin was extracted from pomegranates which were 
purchased from local market in Bhiwani, Haryana (India). 
Peels were authenticated from National Institute of 
Science Communication and Information Resources, New 
Delhi, India. The common excipients like methanol, 
ethanol, acetone, potassium dihydrogen phosphate, 
disodium hydrogen phosphate and sodium chloride were 
obtained from Loba Chemie Pvt. Ltd., Mumbai. Diethyl 
ether was obtained from Central Drug House Pvt. Ltd., 
New Delhi. Span 60 and Cholesterol were obtained from 
S.D. Fine Chemicals Ltd., Mumbai, India. 
METHODS  
1. Extraction, Isolation and Purification of Punicalagin 
from peels of Punica granatum 
1.1 Extraction and Isolation of Punicalagin from peels 
of Punica granatum  
Fruits were washed, separated from seeds and juice and 
cleaned to yield husks/peels. Peels of the Punica 
granatum were dried in shade and powdered them with 
the help of blender. Powdered husk was macerated with 
water and methanol for 7 days with occasional stirring. 
After maceration process was completed, thick husk puree 
was squeezed by hand and filtered through muslin cloth to 
yield dark brown aqueous extract. The column having 
Sephadex LH-20 used as stationary phase and prepared 
for chromatography by pre-washing in methanol and pre-
equilibrated in water for 12 hr. The aqueous extract was 
divided into portions and adsorbed onto the Sephadex LH-
20. Each column was eluted with excess amount of 
distilled water until sugary pale yellow elute was clear in 
colour. The adsorbed tannins were eluted with methanol to 
yield dark brown solution. The collected fractions were 
then passed through C18 catridges (Waters Sep-Pak® Vac 
20cc) and eluted with methanol to obtain the yellowish 
brown solution which contained pure compound, 
Punicalagin. The methanol was removed by Rota-
evaporator in vacuo at low temp. (37⁰C) and obtained the 
dark brown powder as TPT (total pomegranate tannins)1. 
1.2 Purification of Punicalagin from TPT Sephadex 
LH-20 resin column was used to isolate the pure 
compound from TPT. TPT obtained was adsorbed onto a 
Sephadex LH-20 column that was pre-equilibrated with 
water: methanol (8:2 v/v) and eluted with increasing 
amount of methanol. The fraction was evaporated in 
vacuo and then re-chromatography was done by pre-
equilibrating column with ethanol. Elution was done with 
increasing amounts of water and acetone then to ethanol: 
water: acetone (6:3:1 v/v/v) and finally with ethanol: 
acetone (1:1 v/v). The fraction was collected and then 
evaporated in vacuo to obtain yellowish brown powder as 
Punicalagin1. 
2. Preformulation Studies of Punicalagin 
2.1 Organoleptic Properties The organoleptic properties 
include physical state, colour and odour was done by 
visual inspection. 
2.2 TLC Identification Test 
 i) Preparation of sample- The powdered drug (0.5g) was 
macerated in methanol for 4 days. The extract was filtered 
and process was repeated thrice. The filtered extract was 
pooled, evaporated to dryness under reduced pressure and 
residue was dissolved in methanol.  
ii) Preparation of Solvent system- Chloroform: Ethyl 
acetate: Formic acid: Methanol in a ratio of 4: 5.2: 0.6: 0.2 
was mixed to prepare solvent system. Spotting of the 
sample was done with the help of capillary on TLC plate. 
The plate was then placed in the solvent system till the 
saturation point was reached. 
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iii)  Visualisation- TLC plate was dipped in a solution 
consisting of anisaldehyde (0.5ml), glacial acetic acid (9.5 
ml), methanol (85ml) and conc. sulphuric acid (5ml) for a 
few seconds. It was then heated at 110⁰C in hot air oven 
till coloured band appeared and Rf value was then 
calculated as in equation (1).  
 
2.3 Chemical identification test- To identify the drug 
chemically, a pinch of drug was taken in a test tube and 2 
ml of ferric chloride solution was added to it. Presence of 
a colour shows the presence of tannin. 
2.4 Characterisation of Punicalagin  
2.4.1 UV spectroscopy Punicalagin was dissolved in 
phosphate buffer saline pH 7.4 and the sample was 
scanned at wavelength ranging from 200-400nm by UV 
spectrophotometer. The absorption maxima were 
compared with that available in the literature12.   
2.4.2 IR spectroscopy IR spectroscopy of Punicalagin 
was performed using FTIR 8400S (Shimadzu). KBr 
pellets of Punicalagin were prepared by applying a 
pressure of 8 tons in a hydraulic press. The pellets were 
scanned over a wave number range of 4000–400 cm-1.The 
spectrum obtained was interpreted by the literature13. 
3. Standard UV Plots 
3.1 Determination of absorbance maxima (λmax) 
Punicalagin (10mg) was accurately weighed and 
transferred to a 100 ml volumetric flask. To this, pH 7.4 
PBS was added to dissolve the drug. From this solution, 1 
ml of solution was pipetted out in 10 ml volumetric flask 
and volume was made upto 10 ml with distilled water. The 
sample was scanned on a double beam UV-visible 
spectrophotometer. An absorbance maximum of 
Punicalagin was determined in pH 7.4 PBS. 
3.2 Standard plot of Punicalagin in pH 7.4 Phosphate 
buffer The standard plot of Punicalagin was prepared in 
pH 7.4 PBS. 10 mg of drug was weighed accurately and 
dissolved in 100 ml of pH 7.4 PBS. Appropriate dilutions 
were made with buffer to obtain test solutions ranging 
from 5µg/ml to 35µg/ml. The absorbance of the drug in 
the buffer was measured on a double beam UV-visible 
spectrophotometer at λmax of 253.6nm against the 
respective blank. 
4. Compatibility Study 
4.1 Physical characterisation of drug excipient mixture 
Drug and each excipient were separately passed through 
sieve # 20. Drug and each excipient were weighed in the 
ratio of 1:1 and mixed properly with 15 ml of water for 
injection (WFI) as shown in table 1. Different drug 
excipient mixtures were introduced into glass vials 
containing 15 ml of water covered with rubber caps which 
were followed by labelling. Then the vials were kept 
under three different conditions, one at 5 ± 3°C 
(refrigerated temperature), 25 ± 2°C (room temperature) 
and 40 ± 2°C/ 75 ± 5% RH. Observations were taken on 
0th, 7th, 14th, 21st and 28th day for physical compatibility. 
4.2 Chemical characterisation of drug excipient 
mixture  
For chemical compatibility, the study was carried out by 
taking the different drug excipient mixtures after 28th day 
and analyzed spectrophotometrically by UV. 
Table 1: Composition for compatibility study of 
Punicalagin with excipients 
S.No. Drug+ Excipient+ WFI Ratio of drug and 
excipients 
1. Drug + WFI 1:1 
2. Drug+ Span 60+ WFI 1:1 
3. Drug+ Cholesterol+ WFI 1:1 
4.  All excipients+ WFI 1:1 
5. Drug+ all excipients+ WFI 1:1 
 
5. Preparation and Purification of Niosomes 
5.1 Preparation of niosomes by ether injection method  
Niosomes were prepared using Ether injection method14. 
Drug, surfactant and cholesterol were used in the ratios as 
indicated in Table 2. Mixture of surfactant (Span 60) and 
cholesterol dissolved in a mixture of diethyl ether and 
chloroform was slowly introduced through 20-gauge 
needle into warm aqueous solution of Punicalagin 
maintained at 20°C. Evaporation of ether leads to 
formation of single layered vesicles. 
5.2 Purification of niosomes by centrifugation method 
The prepared niosomes were separated from unentrapped 
drug by centrifugation method15. Niosome suspension was 
centrifuged at 40,000 rpm (1,37,088 G)  for 30 minutes. 
Clear supernatant was removed by pipetting and 
remaining sediment i.e. niosomes containing only 
entrapped drug were obtained for further evaluation. 
Table 2: Composition of niosomal formulations of 
Punicalagin 





1. F1 Span 60 1:1:1 
2. F2 Span 60 2:1:1 
3. F3 Span 60 3:1:1 
4. F4 Span 60 4:1:1 
5. F5 Span 60 5:1:1 
6. F6 Span 60 6:1:1 
7. F7 Span 60 7:1:1 
8. F8 Span 60 8:1:1 
9. F9 Span 60 9:1:1 
10. F10 Span 60 10:1:1 
6. Evaluation of niosomes 
6.1 Optical microscopy The morphology of prepared 
niosomes was done by optical microscopy. The 
photomicrographs of the preparations were obtained with 
the help of photomicroscope at 1000 X. 
6.2 Micromeritics studies For the micromeritics study, 
the niosomes were probe sonicated and then the vesicle 
size and size distribution profile were determined using 
dynamic light scattering (DLS) method (Malvern 
Instruments Ltd, Worcestershire, UK). Particle size 
analysis was done by using particle size analyser. 
--- (1) 
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6.3 Entrapment efficiency Ultracentrifugation technique 
was adopted for the removal of the unentrapped drug. The 
centrifuged niosomes were lysed with 0.1% v/v Triton X-
100 and left for 1 hour and filtered to separate drug from 
vesicles. Thereafter dilutions were made and solution was 
analyzed spectrophotometrically employing ultraviolet-
visible spectrophotometer. The entrapment efficiency was 
calculated by using following equation: 
 
6.4 Morphology and structure of vesicles The prepared 
and optimized formulations were characterized for 
morphology (i.e. shape and lamellarity) employing 
Hitachi TEM analyzer.  
6.5 Zeta potential analysis Zeta potential of niosomal 
preparation is related to the stability of niosomes. Zeta 
potential indicates the degree of repulsion between 
adjacent similarly charged particles for small molecules 
and particles, a high value of zeta potential confers 
stability, i.e. the solution or dispersion will resist 
aggregation. Zeta potential for niosomal formulation was 
performed using Zeta sizer Beckman coulter instrument. 
6.6 Stability studies of Punicalagin containing 
niosomes Physical stability studies were carried out to 
investigate the leaching of drug from niosomes (in a 
suspension form) during storage. The optimized niosomal 
formulation (F7) composed of Span 60 and cholesterol in 
7:1 molar ratio were sealed in 20 ml glass vials and stored 
at refrigeration temperature (5 ± 3°C) for a period of 2 
months. Samples were withdrawn at definite time interval 
of 15 days and the percentage entrapment of the drug was 
determined as described previously after separation from 
unentrapped drug. 
RESULTS  
1. Preformulation studies 
1.1 Organoleptic properties  
 
Figure 2: Punicalagin 
1.2 TLC Identification test Purple pink colour was 
appeared and Rf value was observed 0.53 (whereas 
reported value of Rf is 0.58 in ICMR) as shown in figure 
3. 
 
Figure 3: TLC showing detection of Punicalagin 
1.3 Chemical identification test On addition of ferric 
chloride to small amount of drug, a blue colour was 
appeared that indicated the presence of hydrolysable 
tannin. 
1.4 Characterisation of Punicalagin 
1.4.1 UV spectroscopy the absorbance maximum (λmax) 
of Punicalagin in PBS pH7.4 was determined which are 
shown in figure 4. The max of Punicalagin in phosphate 
buffer pH 7.4 was found to be 253.6 nm. 
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1.4.2 IR spectroscopy 
 
Figure 5: IR spectra of Punicalagin 
2. Standard UV plot of Punicalagin in pH 7.4 
Phosphate buffer Standard plot of punicalagin was found 
to be linear with R2 = 0.9978; showing proportional 
increase in the absorbance with concentration which is 
shown in figure 6 and data is represented in table 5.  
 
Figure 6: Standard plot data of Punicalagin in PBS pH 7.4 
Absorbance range of Punicalagin was found to be 0.154 to 
0.855 nm. 
3. Compatibility Study 
3.1 Physical characterisation of drug excipient mixture 
The compatibility study of Punicalagin with various 
excipients showed that there was no colour change as well 
as there was no microbial growth occurred in the solution 
as well as in powder form as shown in table 6. This 
showed that drug is physically compatible with the 
excipients. 
3.2 Chemical characterisation of drug excipient 
mixture For chemical compatibility studies, different 
drug-excipient mixtures were analyzed by UV 
spectroscopy that showed that there is no change in max 
i.e. 253.6 nm which are shown in figure 7. 
4. Evaluation of niosomes 
4.1 Optical microscopy The photomicrographs of 
prepared niosomes are shown below in figure 8. Single 
unilamellar niosomes were observed at 1000X by optical 
microscopy. The niosomes were found to be spherical in 
shape. 
4.2 Micromeritics studies Particle size analysis and size 
distribution of the sonicated niosomes was measured by 
Dynamic Light Scattering phenomenon using a Malvern 
Zeta Sizer instrument. The average particle size and PDI 
values are given in table 7. The average particle sizes of 
the sonicated niosomes were found to be in nanometer 
range which lies in range of 240.6nm – 625.2nm. The PDI 
value which characterizes the uniformity of vesicles in 
suspension that lies in range of 0.226 - 0.548.  
4. Evaluation of niosomes 
4.1 Optical microscopy The photomicrographs of 
prepared niosomes are shown below in figure 8. Single 
unilamellar niosomes were observed at 1000X by optical 
microscopy. The niosomes were found to be spherical in 
shape. 
4.3 Entrapment efficiency According to the entrapment 
efficiency calculated, it was found that F5, F6 and F7 has 
greater entrapment efficiency as compared to other 
formulations whereas F7 has maximum entrapment 
efficiency of 65.93% when compared with F5 and F6 as 
shown in table 8 and figure 10. Thus F7 was selected for 
formulating gel. 
4.4 Morphology and structure of vesicles The 
transmission electron micrographs of unilamellar 
niosomes of optimised formulation (F7) composed of span 
60 and cholesterol in 7:1 molar ratio are shown in figure 
11 (a) and (b). They reveal the presence of well identified 
and nearly perfect spheres. In figure 11 (a), the size of 
niosomes lies in range of 37.6 nm to 43.6 nm whereas in 
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(a)     (b) 
 
(c)     (d) 
 
(e)     (f) 
 
 
(g)     (h) 
Figure 7: Compatibility study data of Punicalagin with different excipients done and by UV spectroscopy (a) Drug at 0 th 
day (b) Drug at 28
th
 day (c) Drug+ Span60 at 0
th
 day (d) Drug+ Span60 at 28
th
 day (e) Drug+ Cholesterol at 0
th
 day (f) 
Drug+ Cholesterol at 28th day (g) Drug+ Mixture of all excipients at 0th day (h) Drug+ Mixture of all excipients at 28th day. 
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(a)      (b)         (c) 
  
(d)    (e)     (f) 
  




Figure 8: Photomicrographs of different formulations at 1000 X (a) F1 (b) F2 (c) F3 (d) F4 (e) F5 (f) F6 (g) F7 (h) F8 (i) F9 
(j) F10 
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Figure 10: Comparison of entrapment efficiency of all formulations 
  
 
Formulations                            (a) 
Particle size range 
Formulations                           (b) 
P.D.I. range 
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(a) 
(b) 
Figure 11: TEM micrographs of optimized niosomes (F7) 
4.5 Zeta potential analysis Zeta potential of the optimized formulation (F7) as shown in figure 12 which was found to be -
27.2 mV depicts the stability of niosomal formulation. 
 
Figure 12: Zeta potential analysis for optimized niosomes (F7) 
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4.6 Stability studies: Drug leakage study Physical 
stability studies were carried out to investigate the 
leaching of drug from the niosomes of optimized 
formulation (F7) during storage at refrigerator 
temperature. The percentage of entrapment efficiency of 
Punicalagin after a period of 2 months got reduced to 25% 
as shown in table 9. 
DISCUSSION  
Punicalagin which was extracted, isolated and purified 
from the peels of the Punica granatum, was identified by 
carrying out chemical identification test, thin layer 
chromatography (TLC), UV spectrophotometry and FTIR. 
Compatibility studies of Punicalagin with the excipients 
used during the work were conducted for 28 days and 
observed that drug is compatible with the excipients 
physically and chemically. On the basis of the findings, it 
can be stated that the formulation F7 is the best 
formulation from all the other formulations which were 
prepared by different compositions of Span 60. The F7 
formulation has greater entrapment efficiency as 
compared to other formulations, as F7 showed 65.93% 
whereas F5 and F6 showed 56.68% and 59% respectively. 
Also, F7 has particle size of lowest value as compared to 
others i.e. 259.5 nm as shown in figure 13. TEM, zeta 
potential and stability studies were conducted for the best 
formulation F7. TEM studies showed that niosomes in F7 
are nearly perfectly spheres whereas zeta potential study 
showed the stability of formulation F7. The future 
perspective of this study is that further experiments can be 
carried out by incorporating this drug into different 
vesicular system and their comparison or by using 
different non-ionic surfactants in different ratios or by 
changing the amount of cholesterol 
  
Figure 13: Particle size distribution and Particle size analysis of F7 
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Table 3: Preformulation parameters and their observation 
 
Table 4: IR spectra showing the peaks of functional groups present in Punicalagin 
Wave number cm
-1
 The peak corresponds to 
Observed value *Reference value 
1589 1560 C-O 
3419 and 3720 3400-3550 O-H 
1683 1680 C=O conjugated with aliphatic C=C 
1261-1242 1270 -1230 -O- (Aralkyl ether) 
1112 and 1350 1100 -1300 COOR 
1456-1589 1450 -1600 Aromatic ring 




Table 5: Absorbance data for calibration curve of Punicalagin 
Concentration               
(µg/ml) 
Absorbance* Average ±SD % RSD 
      Abs 1 Abs 2 Abs 3 
0 0 0 0 0 0 0 
5 0.154 0.156 0.153 0.15433 0.00152 0.9897 
10 0.253 0.255 0.253 0.25366 0.00115 0.4552 
15 0.395 0.396 0.394 0.395 0.001 0.2531 
20 0.496 0.493 0.492 0.49366 0.00208 0.4216 
25 0.593 0.599 0.601 0.59766 0.00416 0.6965 
30 0.736 0.743 0.74 0.73966 0.00351 0.4747 
35 0.855 0.857 0.854 0.85533 0.00152 0.1785 
*
Each value is average of three determination, SD = Standard Deviation, %RSD = Percent Relative Standard Deviation 
 








 day by 
physical observation 






Preformulation property Observations 
Physical state Solid as powder 
Colour Yellowish brown (shown in figure 2) 
Odour Pleasant smell 
Physical compatibility study of Punicalagin with different excipients 
Sample (Drug+Excipients) Ratio Appearance at 
0th day 
Observation at different day and condition 
A (7th day);  B (14th day);  C (28th day) 
5°C±3°C 25°C ± 2°C  40°C ± 2°C (75% ± 5%RH) 
   A B C A B C A B C 
Drug + WFI 1:1 Yellow colour √ √ √ √ √ √ √ √ √ 
Span 60 1 White colour √ √ √ √ √ √ √ √ √ 
Cholesterol  1 White colour √ √ √ √ √ √ √ √ √ 
Carbopol 934 1 White colour √ √ √ √ √ √ √ √ √ 
Drug + Span 60 + WFI 1:1:1 Slight yellow  
colour 
√ √ √ √ √ √ √ √ √ 
Drug + Cholesterol + WFI 1:1:1 Slight yellow 
 colour 
√ √ √ √ √ √ √ √ √ 
Drug + Carbopol 934 + WFI 
 
1:1:1 Slight yellow  
colour 
√ √ √ √ √ √ √ √ √ 
Drug+ Span 60 + 
Cholesterol+ Carbopol 934 
11:1:1:1 Slight yellow  
colour 
√ √ √ √ √ √ √ √ √ 
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Table 7: Values of Average particle size and Polydispersity index (P.D.I) for different formulations 
Formulation Particle size range (in nm) P.D.I. range 
F1 334.8 0.548 
F2 279.6 0.227 
F3 291.7 0.214 
F4 278.7 0.236 
F5 240.6 0.304 
F6 336.8 0.270 
F7 259.5 0.226 
F8 294.1 0.324 
F9 440.7 0.505 
F10 625.2 0.438 
 
 
Table 8: Entrapment efficiency of niosomal formulations 
S. No. Formulation name % drug entrapment* 
1 F1 28.97 ± 0.06 
2 F2 32.18 ± 0.06 
3 F3 35.29 ± 0.06 
4 F4 44.96 ± 0.04 
5 F5 56.68 ± 0.12 
6 F6 59.00 ± 0.06 
7 F7 65.93 ± 0.06 
8 F8 55.70 ± 0.08 
9 F9 46.73 ± 0.12 
10 F10 42.50 ± 0.13 
*
Average of three determinants ± S.D. 
 





      
*Average of three determinations ± S.D 
 
Days 5±3°C 
0th day 65.66 ± 0.14 
15th day  62.66 ± 0.03 
30th day 60.16 ± 0.04 
45th day 52.20 ± 0.11 
60st day 49.63 ± 0.10 
